Baxter acquires SuppreMol GmbH and with it SM 101

Baxter International Inc and SuppreMol GmbH announced that Baxter has acquired SuppreMol for EUR 200 million (approximately $225M USD ) before working capital and other adjustments. SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases.The acquisition includes SuppreMol's early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases, focusing on the modulation of Fc receptor signaling pathways, an immune target that could have broad applications in autoimmune disorders. In addition to the portfolio, Baxter also acquires and will continue to operate SuppreMol's operations in Munich . SuppreMol's pipeline includes lead candidate SM 101, an investigational immunoregulatory treatment that has completed Phase IIa studies in idiopathic thrombocytopenic purpura (ITP, a disorder causing low platelet levels) and systemic lupus erythematosus (SLE, a disorder in which the immune system attacks healthy tissue). SM 101's Phase IIa data, presented during the American College of Rheumatology's 2014 annual meeting, showed a dose response in multiple endpoints among patients with SLE treated with either one of two different doses of SM 101 for six months. The pipeline also includes technologies with potential therapeutic applications in other autoimmune diseases as well as IgE-mediated allergic diseases.